Combination Immune Checkpoint Inhibition: Is First Line Best? von McArthur, Grant A

Volltext

The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma von SHEPPARD, Karen E, MCARTHUR, Grant A

Volltext

Dermatofibrosarcoma protuberans: recent clinical progress von McArthur, Grant

Volltext

Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53 von Bywater, Megan J., Poortinga, Gretchen, Sanij, Elaine, Hein, Nadine, Peck, Abigail, Cullinane, Carleen, Wall, Meaghan, Cluse, Leonie, Drygin, Denis, Anderes, Kenna, Huser, Nanni, Proffitt, Chris, Bliesath, Joshua, Haddach, Mustapha, Schwaebe, Michael K., Ryckman, David M., Rice, William G., Schmitt, Clemens, Lowe, Scott W., Johnstone, Ricky W., Pearson, Richard B., McArthur, Grant A., Hannan, Ross D.

Volltext

Targeting Oncogenic Drivers and the Immune System in Melanoma von MCARTHUR, Grant A, RIBAS, Antoni

Volltext

Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual von Gershenwald, Jeffrey E., Scolyer, Richard A., Hess, Kenneth R., Sondak, Vernon K., Long, Georgina V., Ross, Merrick I., Lazar, Alexander J., Faries, Mark B., Kirkwood, John M., McArthur, Grant A., Haydu, Lauren E., Eggermont, Alexander M. M., Flaherty, Keith T., Balch, Charles M., Thompson, John F., Gershenwald, Jeffrey E., Scolyer, Richard A., Atkins, Michael B., Balch, Charles M., Barnhill, Raymond L., Bilimoria, Karl Y., Buzaid, Antonio C., Byrd, David R., Cochran, Alistair J., Eggermont, Alexander M. M., Elder, David E., Faries, Mark B., Flaherty, Keith T., Garbe, Claus, Gardner, Julie M., Gimotty, Phyllis A., Halpern, Allan C., Haydu, Lauren E., Hess, Kenneth R., Johnson, Timothy M., Kirkwood, John M., Lazar, Alexander J., Lee, Anne W. M., Long, Georgina V., McArthur, Grant A., Mihm Jr, Martin C., Prieto, Victor G., Ross, Merrick I., Sober, Arthur J., Sondak, Vernon K., Thompson, John F., Wong, Sandra L., Delman, Keith A., Santinami, Mario, Maurichi, Andrea, Nagore, Eduardo, Faries, Mark B., Thompson, John F., Scolyer, Richard A., McArthur, Grant A., Gyorki, David E., Henderson, Michael, Stratigos, Alexander J., Gogas, Helen, Gershenwald, Jeffrey E., Haydu, Lauren E., Rossi, Carlo Riccardo, Sommariva, Antonio

Volltext

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study von Long, Georgina V, Atkinson, Victoria, Lo, Serigne, Sandhu, Shahneen, Guminski, Alexander D, Brown, Michael P, Wilmott, James S, Edwards, Jarem, Gonzalez, Maria, Scolyer, Richard A, Menzies, Alexander M, McArthur, Grant A

Volltext

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial von Ascierto, Paolo A, McArthur, Grant A, Dréno, Brigitte, Atkinson, Victoria, Liszkay, Gabrielle, Di Giacomo, Anna Maria, Mandalà, Mario, Demidov, Lev, Stroyakovskiy, Daniil, Thomas, Luc, de la Cruz-Merino, Luis, Dutriaux, Caroline, Garbe, Claus, Yan, Yibing, Wongchenko, Matthew, Chang, Ilsung, Hsu, Jessie J, Koralek, Daniel O, Rooney, Isabelle, Ribas, Antoni, Larkin, James

Volltext

Dysregulation of the basal RNA polymerase transcription apparatus in cancer von Bywater, Megan J., Pearson, Richard B., McArthur, Grant A., Hannan, Ross D.

Volltext

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma von Flaherty, Keith T, Puzanov, Igor, Kim, Kevin B, Ribas, Antoni, McArthur, Grant A, Sosman, Jeffrey A, O'Dwyer, Peter J, Lee, Richard J, Grippo, Joseph F, Nolop, Keith, Chapman, Paul B

Volltext

A Microenvironment-Induced Myeloproliferative Syndrome Caused by Retinoic Acid Receptor γ Deficiency von Walkley, Carl R., Olsen, Gemma Haines, Dworkin, Sebastian, Fabb, Stewart A., Swann, Jeremy, McArthur, Grant A., Westmoreland, Susan V., Chambon, Pierre, Scadden, David T., Purton, Louise E.

Volltext

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation von Chapman, Paul B, Hauschild, Axel, Robert, Caroline, Haanen, John B, Ascierto, Paolo, Larkin, James, Dummer, Reinhard, Garbe, Claus, Testori, Alessandro, Maio, Michele, Hogg, David, Lorigan, Paul, Lebbe, Celeste, Jouary, Thomas, Schadendorf, Dirk, Ribas, Antoni, O'Day, Steven J, Sosman, Jeffrey A, Kirkwood, John M, Eggermont, Alexander M.M, Dreno, Brigitte, Nolop, Keith, Li, Jiang, Nelson, Betty, Hou, Jeannie, Lee, Richard J, Flaherty, Keith T, McArthur, and Grant A

Volltext

BRAF, a target in melanoma von Flaherty, Keith T., McArthur, Grant

Volltext

Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor von KIM, Kevin B, KEFFORD, Richard, GONZALEZ, Rene, OTT, Patrick A, LONG, Georgina V, GARDNER, Olivia S, OUELLET, Daniele, YANMEI XU, DEMARINI, Douglas J, LE, Ngocdiep T, PATEL, Kiran, LEWIS, Karl D, PAVLICK, Anna C, INFANTE, Jeffrey R, RIBAS, Antoni, SOSMAN, Jeffrey A, FECHER, Leslie A, MILLWARD, Michael, MCARTHUR, GrantA, HWU, Patrick

Volltext

Radiotherapy Complements Immune Checkpoint Blockade von Ngiow, Shin Foong, McArthur, Grant A., Smyth, Mark J.

Volltext

Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma von RIBAS, Antoni, KEFFORD, Richard, LORIGAN, Paul, KENDRA, Kari L, MAIO, Michele, TREFZER, Uwe, SMYLIE, Michael, MCARTHUR, Grant A, DRENO, Brigitte, NATHAN, Paul D, MACKIEWICZ, Jacek, KIRKWOOD, John M, MARSHALL, Margaret A, GOMEZ-NAVARRO, Jesus, BO HUANG, PAVLOV, Dmitri, HAUSCHILD, Axel, PUNT, Cornelis J. A, HAANEN, John B, MARMOL, Maribel, GARBE, Claus, GOGAS, Helen, SCHACHTER, Jacob, LINETTE, Gerald

Volltext

Survival of patients with advanced metastatic melanoma: the impact of novel therapies–update 2017 von Ugurel, Selma, Röhmel, Joachim, Ascierto, Paolo A., Flaherty, Keith T., Grob, Jean Jacques, Hauschild, Axel, Larkin, James, Long, Georgina V., Lorigan, Paul, McArthur, Grant A., Ribas, Antoni, Robert, Caroline, Schadendorf, Dirk, Garbe, Claus

Volltext

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF -Mutant Melanoma von Delord, Jean-Pierre, Robert, Caroline, Nyakas, Marta, McArthur, Grant A, Kudchakar, Ragini, Mahipal, Amit, Yamada, Yasuhide, Sullivan, Ryan, Arance, Ana, Kefford, Richard F, Carlino, Matteo S, Hidalgo, Manuel, Gomez-Roca, Carlos, Michel, Daniela, Seroutou, Abdelkader, Aslanis, Vassilios, Caponigro, Giordano, Stuart, Darrin D, Moutouh-de Parseval, Laure, Demuth, Tim, Dummer, Reinhard

Volltext

A First-Time-In-Human Phase I Clinical Trial of Bispecific Antibody-Targeted, Paclitaxel-Packaged Bacterial Minicells von Solomon, Benjamin J, Desai, Jayesh, Rosenthal, Mark, McArthur, Grant A, Pattison, Scott T, Pattison, Stacey L, MacDiarmid, Jennifer, Brahmbhatt, Himanshu, Scott, Andrew M

Volltext

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma von Larkin, James, Ascierto, Paolo A, Dréno, Brigitte, Atkinson, Victoria, Liszkay, Gabriella, Maio, Michele, Mandalà, Mario, Demidov, Lev, Stroyakovskiy, Daniil, Thomas, Luc, de la Cruz-Merino, Luis, Dutriaux, Caroline, Garbe, Claus, Sovak, Mika A, Chang, Ilsung, Choong, Nicholas, Hack, Stephen P, McArthur, Grant A, Ribas, Antoni

Volltext